These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 31595162)

  • 1. Rictor ablation in BMSCs inhibits bone metastasis of TM40D cells by attenuating osteolytic destruction and CAF formation.
    Liu Z; Wang H; He J; Yuan X; Sun W
    Int J Biol Sci; 2019; 15(11):2448-2460. PubMed ID: 31595162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Deletion of Rictor in BMSCs Reduces the Biological Activity of K7M2 Cells and Mitigates OS-Induced Bone Destruction.
    Lu J; Dai D; Zhang J; Wang R; Miao D; Sun W
    Stem Cells; 2023 Jun; 41(6):672-683. PubMed ID: 37099695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
    Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
    Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rictor/mTORC2 loss in osteoblasts impairs bone mass and strength.
    Liu DM; Zhao L; Liu TT; Jiao PL; Zhao DD; Shih MS; Tao B; Sun LH; Zhao HY; Liu JM
    Bone; 2016 Sep; 90():50-8. PubMed ID: 27262777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTH(1‑34) activates the migration and adhesion of BMSCs through the rictor/mTORC2 pathway.
    Lv Z; Muheremu A; Bai X; Zou X; Lin T; Chen B
    Int J Mol Med; 2020 Dec; 46(6):2089-2101. PubMed ID: 33125102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
    Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
    Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
    Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
    Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTORC2/AKT/HSF1/HuR constitute a feed-forward loop regulating Rictor expression and tumor growth in glioblastoma.
    Holmes B; Benavides-Serrato A; Freeman RS; Landon KA; Bashir T; Nishimura RN; Gera J
    Oncogene; 2018 Feb; 37(6):732-743. PubMed ID: 29059166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
    Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-transforming growth factor ß antibody treatment rescues bone loss and prevents breast cancer metastasis to bone.
    Biswas S; Nyman JS; Alvarez J; Chakrabarti A; Ayres A; Sterling J; Edwards J; Rana T; Johnson R; Perrien DS; Lonning S; Shyr Y; Matrisian LM; Mundy GR
    PLoS One; 2011; 6(11):e27090. PubMed ID: 22096521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. mTORC2/Rictor is essential for coelomocyte endocytosis in Apostichopus japonicus.
    Lv Z; Yue Z; Shao Y; Li C; Zhao X; Guo M
    Dev Comp Immunol; 2021 May; 118():104000. PubMed ID: 33444645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of microRNA-424 relieved diabetic nephropathy by targeting Rictor through mTOR Complex2/Protein Kinase B signaling.
    Wang G; Yan Y; Xu N; Hui Y; Yin D
    J Cell Physiol; 2019 Jul; 234(7):11646-11653. PubMed ID: 30637733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rictor/mTORC2 involves mitochondrial function in ES cells derived cardiomyocytes via mitochondrial Connexin 43.
    Wang JD; Shao Y; Liu D; Liu NY; Zhu DY
    Acta Pharmacol Sin; 2021 Nov; 42(11):1790-1797. PubMed ID: 33547375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Rictor/mTORC2 regulates blood-testis barrier and spermatogenesis in mice].
    Dong HL; Wu HY; Fu Y; Dai M; Bai XC; Wang H
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Oct; 37(10):1322-1329. PubMed ID: 29070461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2.
    Guo Z; Zhang X; Zhu H; Zhong N; Luo X; Zhang Y; Tu F; Zhong J; Wang X; He J; Huang L
    Oncol Rep; 2021 Feb; 45(2):523-534. PubMed ID: 33416177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
    Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
    PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A germline-specific role for the mTORC2 component Rictor in maintaining spermatogonial differentiation and intercellular adhesion in mouse testis.
    Bai S; Cheng L; Zhang Y; Zhu C; Zhu Z; Zhu R; Cheng CY; Ye L; Zheng K
    Mol Hum Reprod; 2018 May; 24(5):244-259. PubMed ID: 29518209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
    Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
    J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
    Beck C; Rodriguez-Vargas JM; Boehler C; Robert I; Heyer V; Hanini N; Gauthier LR; Tissier A; Schreiber V; Elofsson M; Reina San Martin B; Dantzer F
    Cell Death Differ; 2019 Sep; 26(9):1615-1630. PubMed ID: 30442946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.